Patents by Inventor Oliver Schroeder
Oliver Schroeder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965263Abstract: The invention relates to a substrate holding and locking system for chemical and/or electrolytic surface treatment of a substrate in a process fluid and a corresponding method. The system comprises a first element, a second element, a reduced pressure holding unit and a magnetic locking unit. The first element and the second element are configured to hold the substrate between each other. The reduced pressure holding unit comprises a pump to reduce an interior pressure inside the substrate holding and locking system below atmospheric pressure. The magnetic locking unit is configured to lock the first element and the second element with each other. The magnetic locking unit comprises a magnet control and at least a magnet. The magnet is arranged at one of the first element and the second element. The magnet control is configured to control a magnetic force between the first element and the second element.Type: GrantFiled: September 2, 2020Date of Patent: April 23, 2024Assignee: SEMSYSCO GMBHInventors: Herbert Ötzlinger, Oliver Knoll, Raoul Schröder, Markus Gersdorff, Thomas Wirnsberger, Georg Hofer, Andreas Gleissner
-
Patent number: 11938522Abstract: The invention relates to a module for chemically processing a substrate, a method for chemically processing a substrate and a use of a module for chemically processing a substrate and in particular a large substrate. The module for chemically processing a substrate comprises: an immersion chamber, a spray unit, and a motion unit (14). The immersion chamber is configured to receive a first liquid and the substrate, so that the substrate is immersed in the liquid. The spray unit comprises a plurality of spray nozzles, which are configured to spray a second liquid within the immersion chamber. The motion unit is configured to provide a relative motion between the substrate and the spray unit.Type: GrantFiled: December 1, 2020Date of Patent: March 26, 2024Assignee: SEMSYSCO GMBHInventors: Andreas Gleissner, Herbert Ötzlinger, Raoul Schröder, Oliver Knoll
-
Publication number: 20230111363Abstract: The present invention relates to antibodies that specifically bind human monocarboxylate transporter 1 (MCT1) (“anti-human MCT1 antibodies”), compositions comprising such anti-human MCT1 antibodies, and methods of using such anti-human MCT1 antibodies.Type: ApplicationFiled: September 14, 2022Publication date: April 13, 2023Inventors: Frank Charles Dorsey, Joseph Benjamin Granger, Kira Vladimirovna Rubtsova, Oliver Schroeder, Wei Wang
-
Patent number: 11492395Abstract: Angiopoietin-like protein (ANGPTL)3/8 fusion proteins are disclosed. Nucleic acid constructs encoding ANGPTL3/8 fusion proteins also are disclosed. Methods of making and using the same also are disclosed, especially for generating antibodies against ANGPTL3 and/or ANGPTL8.Type: GrantFiled: January 19, 2021Date of Patent: November 8, 2022Assignee: Eli Lilly and CompanyInventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
-
Publication number: 20220110537Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.Type: ApplicationFiled: December 22, 2021Publication date: April 14, 2022Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
-
Patent number: 11267882Abstract: Provided are antibodies, or an antigen-binding fragment thereof, that binds human IL-21, These antibodies are useful in immunoassays of IL-21 levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for determining the presence of IL-21 and/or quantifying IL-21 levels, and for diagnostic, prognostic and predictive purpose, and or optimizing therapeutic regimens in patients in which IL-21 signaling is implicated in pathogenesis.Type: GrantFiled: March 24, 2017Date of Patent: March 8, 2022Assignee: ELI LILLY AND COMPANYInventors: Stuart Willis Bright, Julian Davies, Andrea Paula Martin, Joshua Dade Poorbaugh, Oliver Schroeder, Karen Leigh Cox, Angus John MacDonald, Xiao-Fen Wang, Sean Edward Sissons
-
Patent number: 11242383Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.Type: GrantFiled: December 13, 2019Date of Patent: February 8, 2022Assignee: Eli Lilly and CompanyInventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
-
Publication number: 20210147530Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.Type: ApplicationFiled: January 19, 2021Publication date: May 20, 2021Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
-
Patent number: 10919959Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodes bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.Type: GrantFiled: December 13, 2019Date of Patent: February 16, 2021Assignee: Eli Lilly and CompanyInventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
-
Publication number: 20200199212Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodes bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.Type: ApplicationFiled: December 13, 2019Publication date: June 25, 2020Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
-
Publication number: 20200199213Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.Type: ApplicationFiled: December 13, 2019Publication date: June 25, 2020Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
-
Publication number: 20190233508Abstract: Provided are antibodies, or an antigen-binding fragment thereof, that binds human IL-21, These antibodies are useful in immunoassays of IL-21 levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for determining the presence of IL-21 and/or quantifying IL-21 levels, and for diagnostic, prognostic and predictive purpose, and or optimizing therapeutic regimens in patients in which IL-21 signaling is implicated in pathogenesis.Type: ApplicationFiled: March 24, 2017Publication date: August 1, 2019Inventors: Stuart Willis Bright, Julian Davies, Andrea Paula Martin, Joshua Dade Poorbaugh, Oliver Schroeder, Karen Leigh Cox, Angus John MacDonald, Xiao-Fen Wang, Sean Edward Sissons
-
Patent number: 9394362Abstract: The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human IL-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.Type: GrantFiled: March 13, 2015Date of Patent: July 19, 2016Assignee: Eli Lilly and CompanyInventors: Julian Davies, Fabio Magrini, Andrea Paula Martin, Neelufar Mozaffarian, Chetankumar N. Patel, Oliver Schroeder
-
Publication number: 20150294239Abstract: A first itinerary comprising a first plurality of first location elements associated with locations to be visited during a trip, each first location element comprising first duration information, first arrival date information, and first departure date information, is maintained. A second itinerary comprising a plurality of transport elements associated with transportation to be used during the trip and a second plurality of second location elements, each second location element associated with a corresponding first location element, each second location element comprising second duration information, second arrival date information, and second departure date information is maintained. Modification information indicating that a duration specified in a selected first location element has been altered is received. A first duration, first arrival date information, or first departure date information in a first location element is adjusted based on the modification information.Type: ApplicationFiled: April 11, 2014Publication date: October 15, 2015Inventors: Madelein Constanza ARAYA HERNANDEZ, Manuel AGUILA YANEZ, Benjamin Sebastian Ariel DIAZ CABALLERO, Michael Harald HAASE, Johannes HEBBELMANN, Danny Enrique PERICH LARA, Fabian Leonardo PERICH LARA, Oliver SCHROEDER, David STAUFFER, Justus Fritz ZEPPENFELD
-
Publication number: 20150266954Abstract: The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human IL-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.Type: ApplicationFiled: March 13, 2015Publication date: September 24, 2015Inventors: Julian Davies, Fabio Magrini, Andrea Paula Martin, Neelufar Mozaffarian, Chetankumar N. Patel, Oliver Schroeder